Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Interest & Investment Income for 10 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 35.17% to $6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.0 million, a 32.43% decrease, with the full-year FY2025 number at $25.0 million, down 32.43% from a year prior.
  • Interest & Investment Income was $6.5 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $5.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $10.7 million in Q3 2024 to a low of $408000.0 in Q3 2021.
  • A 5-year average of $5.1 million and a median of $5.9 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 78.11% in 2021, then skyrocketed 1308.64% in 2022.
  • Ultragenyx Pharmaceutical's Interest & Investment Income stood at $440000.0 in 2021, then surged by 1308.64% to $6.2 million in 2022, then soared by 43.03% to $8.9 million in 2023, then grew by 13.3% to $10.0 million in 2024, then crashed by 35.17% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Interest & Investment Income are $6.5 million (Q4 2025), $5.9 million (Q3 2025), and $5.8 million (Q2 2025).